Delivery Order SPE2DB25D3020-SPE2DB25FWKPS
- Not listed
- The Defense Logistics Agency awarded a $23,543.70 delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of RINVOQ ER 30 mg tablets (30-count units). This competitively awarded, firm fixed-price contract represents a non-set-aside procurement and is scheduled for completion by September 17, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary operations as a major...
- The Defense Logistics Agency awarded a $28,684.94 delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of RINVOQ ER 15 mg tablets (30-count units). This firm fixed-price delivery order, which is set to be completed by September 4, 2025, represents a competitive award with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a major pharmaceutical distributor and critical vendor for federal medical procurement,...
- The Defense Logistics Agency awarded a $12.8K delivery order to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of RINVOQ ER 30 mg tablets (30-count units). This is a firm fixed-price, competitively awarded delivery order with no set-aside designation and an ultimate completion date of September 12, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of RINVOQ ER 15 mg tablets (30-count unit of use packaging) under a firm fixed-price contract valued at $60,356.04, with completion scheduled for September 17, 2025. This non-set-aside competitive award leverages AmerisourceBergen's position as a major pharmaceutical distributor and represents a continuation of the company's extensive support to federal medical...
- The Defense Logistics Agency awarded a $23,192.04 firm fixed-price delivery order to AmerisourceBergen Drug Corp on June 2, 2025, for the supply of RINVOQ ER 30 mg tablets in quantities of 30 units. The contract, which represents a non-competitive delivery order under an existing indefinite delivery vehicle, is scheduled for completion by June 3, 2025, with performance to be fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order falls...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 11, 2025, for RINVOQ ER 45 mg tablets (28-count units) with a ceiling value of $74,205.29. This firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The award was made competitively without set-aside designation, reflecting...
- The Defense Logistics Agency awarded a competitive delivery order to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of RINVOQ ER 30 mg tablets in quantities of 30 units. The contract represents a firm fixed price delivery order with a ceiling value of $38,113.45 and an ultimate completion date of September 15, 2025. This non-set-aside award reflects AmerisourceBergen's continued role as a critical pharmaceutical supplier to the federal government, with performance taking place...
- The Defense Logistics Agency (DLA) awarded a $23,495.73 delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of RINVOQ ER 15 mg tablets (30-count units). This is a firm fixed-price, non-set-aside contract with a completion date of September 11, 2025, and performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a $18,263.06 delivery order to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of RINVOQ ER 15 mg tablets (30-count units). This is a firm fixed-price, non-set-aside contract with performance completion targeted for September 15, 2025, and fulfillment occurring at the contractor's Conshohocken, Pennsylvania facility. The award represents a competitively awarded delivery order under AmerisourceBergen's existing pharmaceutical supply framework...
- The Defense Logistics Agency awarded a $42,773.33 delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on July 23, 2025, with an ultimate completion date of July 24, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and running through December 2026. The place of performance is listed...
- SPE2DB25D3020Indefinite Delivery Contract
- SPE2DB25D3020-SPE2DB25FWKPSDelivery Order
The Defense Logistics Agency awarded a $35,816.58 delivery order to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of RINVOQ ER 30 mg tablets (30-count units). The contract, which is a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical, utilizes firm fixed-price pricing with no set-aside designation, indicating competitive award. Performance will be executed from the company's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of September 16, 2025. AmerisourceBergen Drug Corp serves as a critical pharmaceutical distributor for federal medical procurement, particularly supporting military and veteran healthcare systems through the Defense Logistics Agency. This delivery order represents one of numerous pharmaceutical supply transactions under the company's $999.99 billion comprehensive IDC with DLA Troop Support Medical, which extends through December 2026 and enables the supply of brand-name and generic medications, vaccines, and specialized medical commodities to defense healthcare programs globally.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $35.8k | 9/15/25 |